Cargando…
Request for clarification from Ruiter et al regarding ‘Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study’. Reply to Carstensen B [letter]
Autores principales: | Ruiter, R., Visser, L. E., Stricker, B. H. Ch. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3268967/ http://dx.doi.org/10.1007/s00125-011-2448-2 |
Ejemplares similares
-
Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study
por: Ruiter, R., et al.
Publicado: (2011) -
Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin
por: Stürmer, Til, et al.
Publicado: (2013) -
Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012) -
Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016) -
Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients
por: Jakobsen, Marie, et al.
Publicado: (2012)